Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
7 p, 784.4 KB Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma : A GELTAMO Trial / Cabrero, Monica (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ; Martín García-Sancho, Alejandro (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ; Briones Meijide, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Gayoso, Jorge (Hospital General Universitario Gregorio Marañón) ; Jarque, Isidro (Hospital Universitari i Politècnic La Fe (València)) ; López, Javier (Hospital Universitario Ramón y Cajal (Madrid)) ; Grande García, Carlos (Hospital 12 de Octubre (Madrid)) ; Heras, Inmaculada (Hospital Morales Messeguer) ; Arranz, Reyes (Hospital Universitario de la Princesa (Madrid)) ; Bernal, Teresa (Hospital Universitario Central de Asturias) ; Perez-Lopez, Estefenia (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ; López-Godino, Oriana (Hospital Morales Messeguer) ; Conde, Eulogio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Caballero, Dolores (Hospital Universitario Salamanca i IBSAL (Instituto Biosanitario de Salamanca)) ; Universitat Autònoma de Barcelona
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). [...]
2017 - 10.1016/j.bbmt.2016.10.003
Biology of blood and marrow transplantation, Vol. 23 Núm. 1 (january 2017) , p. 53-59  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.